melanoma

News

Frontline Immune Checkpoint Inhibitors Cost-Effective for Advanced Melanoma

08/07/2020

Nivolumab plus ipilimumab and pembrolizumab are the most cost-effective front-line treatment options for patients with newly diagnosed advanced melanoma and unknown BRAF status, according to a study published in JAMA...

...

08/07/2020

Journal of Clinical Pathways

News

Late-Stage Melanoma Prognosis After Treatment With Novel Therapies

06/18/2020

Melanoma-specific survival rates in the Central Malignant Melanoma Registry (CMMR) and European Organization for Research and Treatment of Cancer (EORTC) stage III data sets are less favorable than those published in...

...

06/18/2020

Journal of Clinical Pathways

Research in Review

Continued Nivolumab After Progression May Improve Outcomes in Melanoma

07/03/2017

JCP Editors

Patients with advanced melanoma who are treated with nivolumab after their first disease progression may experience tumor response without compromising safety, according to an original investigation published in JAMA...

...

07/03/2017

Journal of Clinical Pathways

Research in Review

Does Delayed Lymph Node Biopsy Affect Survival Rates in Melanoma?

06/29/2017

JCP Editors

Recent research compared survival outcomes of patients newly diagnosed with melanoma who received a sentinel lymph node biopsy within 30 days and those who received biopsy after 30 days, published in the Journal of...

Recent...

06/29/2017

Journal of Clinical Pathways

Research in Review

Embedding Palliative Care in Treatment Clinics Improves Access to Care

06/21/2017

JCP Editors

An embedded palliative care program results in earlier and prolonged access to palliative care, according to research published in the Journal of Oncology Practice (published online June 2017;...

An...

06/21/2017

Journal of Clinical Pathways

Research in Review

Imaging Needed to Monitor Melanoma Brain Metastases During PD-1 Therapy

06/03/2017

JCP Editors

Central nervous system imaging is needed during programmed death 1 (PD-1) inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases, according to research presented at...

...

06/03/2017

Journal of Clinical Pathways

Research in Review

Burden on Treatment Costs Impact Quality of Life Among Melanoma Survivors

06/03/2017

JCP Editors

Financial toxicity and excessive financial burden appeared common among melanoma survivors, frequently leading to disease-related distress, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...

...

06/03/2017

Journal of Clinical Pathways

Research in Review

Advanced Melanoma Increases Psychological Burden in Patients

05/25/2017

JCP Editors

Stage III and IV melanoma may have a profound impact on patients’ distress burden, which requires further intervention strategies, according to research that will be presented at the 2017 ASCO Annual Meeting...

Stage...

05/25/2017

Journal of Clinical Pathways

Research in Review

Melanoma Treatment Costs Vary by Insurance Type, Location

04/10/2017

JCP Editors

The treatment of advanced melanoma represents a significant burden to the health system, and differs by insurance type and geographic location, according to the results of a regional analysis. ----- Related...

The...

04/10/2017

Journal of Clinical Pathways

Research in Review

Specialized Surveillance Cost-Effective, Not Linked to Overtreatment in High-Risk Melanoma Population

12/13/2016

JCP Editors

A specialized surveillance program designed to monitor individuals deemed at high risk for melanoma proved cost-effective and may reduce overtreatment rates compared with standard care, according to study results...

A...

12/13/2016

Journal of Clinical Pathways